An ATM test looks for changes in the ATM gene, an important DNA-damage response gene that helps cells recognize and repair broken DNA. In prostate cancer, an ATM alteration can matter for two different reasons: it may be an inherited germline variant that affects cancer risk for the patient and relatives, or it may be a somatic change found only in the tumor. Pathogenic ATM variants are associated with increased prostate cancer risk and, in some studies, more aggressive disease. In advanced prostate cancer, ATM is also included on homologous recombination repair panels used to identify potential treatment options and clinical trials. However, an ATM alteration does not carry exactly the same treatment implications as BRCA1 or BRCA2. Responses to PARP inhibitors have generally been less consistent in ATM-altered prostate cancer than in BRCA2-altered disease. Accurate interpretation therefore depends on the variant classification, whether it is germline or somatic, whether both gene copies are affected, and the clinical setting.
- An ATM result is most important when it identifies a pathogenic or likely pathogenic variant; a variant of uncertain significance should not be treated as a confirmed cancer-risk mutation.
- Germline ATM variants are inherited and can affect relatives, while somatic ATM variants are acquired in the tumor and may not be present in the rest of the body.
- ATM is a DNA-repair gene commonly included in prostate cancer HRR panels, but its treatment implications differ from BRCA1 and BRCA2.
- A positive tumor ATM result may prompt confirmatory germline testing because tumor-only testing cannot always determine whether the change was inherited.
- PARP inhibitor benefit in ATM-altered prostate cancer is less predictable than in BRCA2-altered disease, so the exact mutation and treatment context matter.
Table of Contents
- What the ATM Gene Does
- Germline Versus Somatic ATM Testing
- Who May Need ATM Testing
- How to Read an ATM Test Result
- What ATM Means for Prostate Cancer Risk
- ATM and Treatment Decisions
- Family Implications and Next Steps
What the ATM Gene Does
ATM stands for ataxia-telangiectasia mutated. The gene provides instructions for a protein kinase that senses DNA double-strand breaks and activates a network of repair, cell-cycle, and cell-death signals. In healthy cells, this system helps prevent damaged DNA from being copied and passed on.
When ATM function is lost, cells can accumulate genomic damage. That creates conditions in which cancer can develop and evolve. ATM is therefore considered a tumor-suppressor gene and part of the broader DNA damage response system.
In prostate cancer, ATM is usually discussed alongside other homologous recombination repair, or HRR, genes. A prostate cancer HRR gene panel may include BRCA1, BRCA2, ATM, PALB2, CHEK2, CDK12, and other genes depending on the laboratory and treatment context.
ATM is biologically related to DNA repair, but it is not interchangeable with BRCA2. BRCA1 and BRCA2 participate more directly in homologous recombination repair, whereas ATM acts as a damage-sensing and signaling regulator. That difference helps explain why prostate cancers with ATM alterations do not always respond to DNA-repair-targeted drugs in the same way as BRCA-altered cancers.
A test can examine ATM in several specimen types:
- Blood or saliva for germline testing.
- Tumor tissue from a prostate biopsy, prostatectomy, or metastatic biopsy for somatic testing.
- Circulating tumor DNA in plasma as a liquid-biopsy method for tumor profiling in advanced disease.
The specimen determines what the result can tell you. A blood germline test asks whether the variant is present in essentially all cells and may be inherited. A tumor or plasma test asks what alterations are present in the cancer, which can include both inherited and acquired changes.
Germline Versus Somatic ATM Testing
The most important first question after an ATM result is where the DNA came from.
A germline ATM variant is present from birth. It can be inherited from a parent and passed to children. A person who carries one pathogenic ATM variant is called a heterozygous carrier. Heterozygous pathogenic variants are associated with increased risks of several cancers, including prostate cancer, pancreatic cancer, and female breast cancer. The exact level of risk varies by the specific variant, family history, age, and other modifiers.
A somatic ATM alteration arose in the tumor during the person’s lifetime. It may contribute to cancer biology or treatment sensitivity, but it does not automatically mean relatives are at increased inherited risk.
The distinction can become blurred when tumor testing finds an ATM alteration. A tumor sequencing report may not be able to prove whether the variant is inherited. If a pathogenic or likely pathogenic ATM variant is detected in prostate tumor tissue or circulating tumor DNA, clinicians may recommend a separate germline blood or saliva test.
This confirmatory step matters because tumor-only testing can both miss germline variants and identify variants that only appear germline because of technical or biological factors. Plasma testing also has a special confounder called clonal hematopoiesis, in which age-related blood-cell clones carry mutations that can appear in cell-free DNA. Some DNA-repair genes can be affected, so laboratories use paired blood-cell analysis, variant patterns, and clinical interpretation to reduce false attribution to the tumor.
Another key concept is biallelic loss. Humans generally have two copies of ATM. A tumor may carry one altered copy while the other remains functional, or both copies may be inactivated through mutation, deletion, or another event. Complete loss of ATM function may have stronger biological consequences than a single altered copy, but routine reports do not always establish biallelic status clearly.
Who May Need ATM Testing
ATM is rarely tested alone. It is usually included in a multigene hereditary cancer panel, a prostate tumor next-generation sequencing panel, or an HRR-focused panel.
Current prostate cancer guidance supports germline testing broadly in men with metastatic disease and in selected men with high-risk, node-positive, or otherwise clinically concerning localized disease. Testing is also important when personal or family history suggests an inherited cancer syndrome.
Features that can support germline testing include:
- Metastatic prostate cancer.
- High-risk or very-high-risk localized disease.
- Node-positive prostate cancer.
- Intraductal or cribriform tumor features in appropriate clinical contexts.
- A strong family history of prostate cancer, particularly aggressive, metastatic, or early-onset disease.
- A family history that includes breast, ovarian, pancreatic, colorectal, or other hereditary-cancer-associated malignancies.
- A known pathogenic variant in a cancer-predisposition gene in a blood relative.
Somatic tumor testing is especially important in recurrent or metastatic prostate cancer because genomic findings may affect treatment selection. The metastatic prostate cancer biomarker panel often extends beyond ATM to BRCA1/2, other HRR genes, mismatch repair, microsatellite instability, and additional actionable alterations.
Genetic counseling is valuable before and after germline testing. A counselor can explain what the test can and cannot show, what a positive result might mean for relatives, insurance and privacy considerations, and how to handle uncertain findings.
Testing should not be limited to men with an obvious family history. Small families, adoption, early deaths from unrelated causes, limited knowledge of relatives’ diagnoses, and inheritance through female relatives can all hide hereditary cancer patterns.
How to Read an ATM Test Result
The exact wording on the report matters more than the simple fact that “an ATM variant” was found. Genetic laboratories generally classify variants using categories such as pathogenic, likely pathogenic, uncertain significance, likely benign, or benign.
| Result | What it usually means | Typical clinical approach |
|---|---|---|
| Pathogenic | Strong evidence that the variant disrupts ATM function | Use in hereditary-risk counseling and/or tumor treatment assessment as appropriate |
| Likely pathogenic | High probability that the variant is disease-causing | Usually managed similarly to a pathogenic variant |
| Variant of uncertain significance | Evidence is insufficient or conflicting | Do not use alone for major treatment or family-risk decisions |
| Likely benign or benign | Evidence indicates little or no disease-causing effect | Generally not considered a positive cancer-predisposition finding |
A variant of uncertain significance, or VUS, is not the same as a pathogenic mutation. This is one of the most important rules in genetic testing. A VUS should not normally trigger preventive surgery, cascade testing of relatives as if the variant were disease-causing, or a targeted cancer treatment solely because it appears in ATM.
Variant classifications can change as laboratories collect more population, functional, and family data. The laboratory or genetics clinic may reclassify a VUS later. Patients should keep a copy of the report and maintain contact with the ordering genetics service when practical.
Tumor reports add other details such as variant allele fraction, copy-number loss, loss of heterozygosity, and whether the alteration is predicted to disrupt the protein. These features can help specialists judge whether ATM function is truly lost.
A negative test also needs careful interpretation. It means the panel did not identify a reportable pathogenic variant using the methods performed. It does not eliminate all inherited prostate cancer risk, because unknown genes, variants outside tested regions, polygenic risk, and shared family factors can still contribute.
What ATM Means for Prostate Cancer Risk
A germline pathogenic ATM variant is associated with a moderately increased risk of prostate cancer compared with the general population. Evidence also links ATM pathogenic variants with a higher likelihood of clinically significant or aggressive prostate cancer in some cohorts.
The risk is not a fixed percentage that applies to every carrier. It depends on the exact variant, family history, ancestry, age, and competing health factors. For this reason, professional genetics guidance increasingly favors individualized risk assessment rather than presenting one universal lifetime-risk number.
Men who carry a germline ATM pathogenic variant should discuss prostate screening with a clinician familiar with hereditary cancer. Screening may begin earlier or be performed more intensively than average-risk screening, depending on country-specific guidance and family history. PSA remains the main blood marker used in screening, with MRI and other tests added when appropriate.
A carrier can still have a normal PSA result, and most PSA elevations are not caused by hereditary mutations. ATM status changes the background level of risk; it does not create a unique PSA pattern.
For someone who already has prostate cancer, a germline ATM finding can influence several areas at once. It may support more careful risk assessment, prompt relatives to consider testing, and qualify the patient for clinical trials or molecularly selected treatment strategies in advanced disease.
It is also important to avoid overinterpreting a somatic-only ATM alteration as a statement about inherited risk. If germline testing is negative, a tumor-only ATM change generally does not imply that children or siblings inherited the same variant.
ATM and Treatment Decisions
ATM is included among HRR genes because DNA-repair defects can create sensitivity to PARP inhibition. However, the strength of evidence is gene specific. The clearest and most consistent PARP inhibitor benefit in prostate cancer has been seen with BRCA2, with benefit also established in selected BRCA1-altered disease. ATM-altered tumors have shown less consistent and often smaller responses in trials and real-world series.
This does not mean an ATM result is useless. Depending on the drug, regulatory indication, treatment line, combination regimen, and jurisdiction, an ATM alteration may contribute to eligibility for a PARP inhibitor or a clinical trial. But the oncology team should not assume that an ATM mutation predicts the same response probability as a BRCA1 or BRCA2 alteration.
Several details can change the interpretation:
- Whether the ATM variant is pathogenic or merely uncertain.
- Whether the alteration is germline, somatic, or both.
- Whether the tumor has lost both functional ATM copies.
- Whether ATM protein loss is demonstrated by another method.
- Which PARP inhibitor or combination is being considered.
- Prior androgen-receptor therapy and chemotherapy exposure.
- Other coexisting genomic alterations.
- Current disease burden, symptoms, and pace of progression.
ATM may also be important for trial selection. Research strategies include combinations that exploit DNA-damage response vulnerabilities beyond PARP alone, such as ATR inhibitors and other agents designed for ATM-deficient tumors.
A pathogenic ATM result should therefore trigger a specific treatment discussion, not a generic statement that the cancer is “PARP sensitive.” The distinction protects patients from overestimating the expected benefit of a targeted drug based on the name of the pathway alone.
The biological effect of an ATM alteration also depends on whether the cancer has lost one copy or both functional copies of the gene. A single altered copy may not impair DNA-repair activity as strongly as biallelic loss, in which both copies are inactivated. Tumor sequencing reports do not always establish this clearly, especially when tumor purity is low or copy-number information is incomplete. That detail can matter when an oncologist is judging how strongly an ATM finding supports a DNA-repair-targeted strategy.
ATM should also be interpreted differently from BRCA2 even though both appear on homologous-recombination repair panels. Clinical trials and pooled analyses have generally shown the most consistent PARP-inhibitor benefit in BRCA1/2-altered prostate cancer, particularly BRCA2. Responses in ATM-altered disease have been less frequent and less predictable. An ATM finding can still be clinically important, but it should not be assumed to confer the same treatment sensitivity as a BRCA2 pathogenic variant.
For hereditary risk, the exact laboratory classification is critical. A pathogenic or likely pathogenic germline ATM variant may justify genetic counseling and family-based testing, while a variant of uncertain significance should not be used to label relatives as having an inherited cancer syndrome. Laboratories may reclassify variants as evidence accumulates, so patients with a VUS should keep contact information current and ask how amended reports are communicated.
Family Implications and Next Steps
If germline testing confirms a pathogenic or likely pathogenic ATM variant, the result has implications beyond the patient’s prostate cancer. First-degree relatives—parents, siblings, and children—may each have a chance of carrying the familial variant. Genetic counseling can identify which relatives are appropriate for cascade testing, meaning targeted testing for the known family variant.
A positive family test does not mean that cancer is inevitable. It means screening and prevention discussions can be tailored to a higher inherited risk. Recommendations differ for men and women and may involve breast, prostate, pancreatic, or other cancer surveillance depending on age, sex, family history, and local guidelines.
After receiving an ATM result, useful questions include:
- Is this variant pathogenic, likely pathogenic, or uncertain?
- Was it found in germline DNA, tumor DNA, plasma ctDNA, or more than one source?
- Do I need confirmatory germline testing?
- Does the result suggest one or both ATM copies are inactivated in the tumor?
- How strongly does this alteration predict benefit from the treatment being proposed?
- Would a BRCA-focused or broader HRR result change the recommendation?
- Should relatives meet with a genetic counselor?
- Is there a clinical trial designed for ATM-deficient prostate cancer?
Keep the original laboratory report rather than relying on a handwritten note that simply says “ATM positive.” The precise variant, classification, specimen, and laboratory interpretation are essential for future care.
ATM testing can provide valuable information about hereditary risk and tumor biology, but its meaning is layered. The best interpretation separates inherited risk from tumor-only findings, distinguishes pathogenic variants from VUS results, and treats ATM as its own biomarker rather than assuming it behaves like every other DNA-repair gene.
References
- Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline 2025 (Guideline)
- Germline Testing for Prostate Cancer Patients: Evidence-Based Evaluation of Genes Recommended by NCCN Guidelines 2025
- Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) 2025 (Position Statement)
- Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2) 2025 (Review)
- Germline Genetics of Prostate Cancer 2022 (Review)
Disclaimer
This article is educational and does not replace genetic counseling, oncology care, or individualized screening advice. ATM results must be interpreted according to the exact variant classification, specimen type, family history, and prostate cancer setting. Do not make treatment or family-testing decisions from a VUS or a tumor-only result without qualified clinical interpretation.
